PharmaTelevision - Burnham’s Commitment to Collaborative Research

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Burnham’s Commitment to Collaborative Research

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Robert Zaugg, VP Business Development at the Burnham Institute for Medical Research, gives his perspective of the scientific capability and achievements of the Institute's many locations. The wide range of activities that the Institute has are all funded by federal grants, philanthropists or through collaborations with large pharmaceutical companies. With many pharmaceutical companies turning their attention to early stage research, the Burnham Institute will have an important role to play in the next few years.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Burnham's origins and it's growth as one of the largest independent Medical Research Institutes in the United States.

Fintan Walton:

Hello and welcome to PharmaVentures business review here in San Francisco. On this show I have Robert Zaugg who is the Vice President of Business Development at the Burnham Institute for Medical Research. Welcome to the show.

Robert Zaugg:

Thanks so much for having me.

Fintan Walton:

Pleasure and what we want to do today is to talk about Burnham because it's an institute that's risen to quite a large size in recent years but it's history goes back over 30-years. So to give us a perspectives of Burnham and it's origins, could you just give us how it was founded and where it originally set out and how it's now grown to one of the largest independent Medical Research Institutes in the United States?

Robert Zaugg:

Right, so it was founded as you say about 30-years ago originally as a cancer research institute focusing on early stage cancer research and the mechanisms of oncology and cancer development. It was founded in La Jolla, it's still based in La Jolla, California and Santiago were we've grown to a campus of about 10 acres and 300,000 square feet of lab space and about 700 employees at that location. We recently expanded our operations to Orlando, Florida were we are building a large research institute there they will focus largely on diabetes and obesity research. We've also established a satellite lab in Santa Barbara at the campus of University of California, Santa Barbara that's focused on nanotechnology and in La Jollaitself we've branched out now beyond the cancer to add research capabilities in neuroscience and inflammatory and infectious disease research as well.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Robert Zaugg

VP Business Development Burnham Institute for Medical Research

Dr. Zaugg, VP Business Development, is responsible for the business development activities of the Institute, including technology licensing and establishment of strategic alliances in support of the scientists in La Jolla, Santa Barbara and at Lake Nona in Orlando, Florida. Dr. Zaugg, has contributed to the successful closing of deals aggregating greater than $500 million over 20 year's in companies spanning from startup biotech environments to large pharmaceutical corporations. In recent year's, Dr. Zaugg has worked as an independent consultant, serving as Interim CEO of several California biotech companies, including DermAegis, Inc., which he also co-founded, and Optime Therapeutics. Dr. Zaugg's, prior affiliations include: General Manager of GTS Proteomics; Vice President of Business Development at Vical, Inc.; Director of Business Development at Triton (now Berlex Biosciences; Assistant Director of Technology Assessment at Sandoznow Novartis. Dr. Zauggalso held positions as Senior Scientist at Teknekron Research in McLean, VA, and served as an intern in the United States Senate as an advisor to the Subcommittee on Science, Technology and Space. Dr. Zauggtrained as a postdoctoral fellow at MIT where his work on immunoglobulin biochemistry was supported by a fellowship from the prestigious Damon Runyon-Walter Winchell Cancer Foundation. He has earned degrees from UCLA (B.A.), Northwestern University (M.S., Ph.D.), and New York University (M.B.A.).

Burnham Institute for Medical Research

Burnham Institute for Medical Research, is dedicated to revealing the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham is one of the fastest growing research institutes in the country with operations in California and Florida. The Institute ranks among the top 4 institutions nationally for NIH grant funding and among the top 25 organizations worldwide for its research impact. Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration , diabetes , infectious, and inflammatory, and childhood diseases. The Institute is known for its world-class capabilities in stem cellresearch and drug discovery technologies.